Characterization of the nicotine uptake and safety of Nordic spirit tobacco-free oral nicotine pouches: A randomized cross-over study
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
0.2% decline in heart rate for Nordic Spirit 11.2 mg ONP 30 min post-exposure.
“0.2% decline in HRT for Nordic Spirit 11.2 mg ONP 30 min post-exposure”
From Comparison of the Health Effects Associated with the Use of Snus and Tobacco-Free Oral Nicotine Pouches: A Systematic Review (2026) · cites this paper as Renard et al. 2025
The Results (Physiological effects) report a 0.2% increase in pulse rate for Nordic Spirit 11.2 mg, not a decline. This measurement was taken 30 minutes after the end of product use. (LLM, conf=0.93)
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredAcute 1% decline in systolic blood pressure for Nordic Spirit 6 mg ONP 30 min post-exposure.
“Acute 1% decline in SBP for Nordic Spirit 6 mg ONP 30 min post-exposure (Renard et al. 2025)”
From Comparison of the Health Effects Associated with the Use of Snus and Tobacco-Free Oral Nicotine Pouches: A Systematic Review (2026) · cites this paper as Renard et al. 2025
The Results (Physiological effects) report a −0.1% change in systolic blood pressure for Nordic Spirit 6 mg at one hour after the start of use, which is 30 minutes after use ended. The claimed direction and timing match, but the cited decline is 0.1%, not 1%. (LLM, conf=0.91)
Experimental — accuracy not yet measured3.2% increase in heart rate for Nordic Spirit 9 mg ONP 30 min post-exposure.
“3.2% increase in HRT for Nordic Spirit 9 mg ONP 30 min post-exposure”
From Comparison of the Health Effects Associated with the Use of Snus and Tobacco-Free Oral Nicotine Pouches: A Systematic Review (2026) · cites this paper as Renard et al. 2025
3% decline in heart rate for Nordic Spirit 6 mg ONP 30 min post-exposure.
“3% decline in HRT for Nordic Spirit 6 mg ONP 30 min post-exposure (Renard et al. 2025)”
From Comparison of the Health Effects Associated with the Use of Snus and Tobacco-Free Oral Nicotine Pouches: A Systematic Review (2026) · cites this paper as Renard et al. 2025
4.5% increase in diastolic blood pressure for Nordic Spirit 6 mg ONP 30 min post-exposure.
“4.5% increase in DBP for Nordic Spirit 6 mg ONP 30 min post-exposure (Renard et al. 2025)”
From Comparison of the Health Effects Associated with the Use of Snus and Tobacco-Free Oral Nicotine Pouches: A Systematic Review (2026) · cites this paper as Renard et al. 2025
During 30 min ONP use, there is an increase in systolic blood pressure up to 3%, diastolic blood pressure up to 7.4%, and heart rate up to 3.2%; 30 min post exposure, there is an increase in systolic blood pressure (3% for 9 mg ONP), diastolic blood pressure (4.5% for 6 mg and 7.4% for 9 mg ONPs), and heart rate (3.2% for 9 mg ONP).
“increase in SBP (up to 3%), DBP (up to 7.4%) and HRT (up to 3.2%) during 30 min ONPs (6 mg and 9 mg nicotine) use.Moreover, 30 min post exposure there was an increase in SBP (3% for 9 mg ONP), DBP (4.5% for 6 mg and 7.4% for 9 mg ONPs) and HR (3.2% for 9 mg ONP) (Renard et al. 2025).”
From Comparison of the Health Effects Associated with the Use of Snus and Tobacco-Free Oral Nicotine Pouches: A Systematic Review (2026) · cites this paper as Renard et al. 2025
1.4% increase in systolic blood pressure for Nordic Spirit 11.2 mg ONP 30 min post-exposure.
“1.4% increase in SBP for Nordic Spirit 11.2 mg ONP 30 min post-exposure”
From Comparison of the Health Effects Associated with the Use of Snus and Tobacco-Free Oral Nicotine Pouches: A Systematic Review (2026) · cites this paper as Renard et al. 2025
3.9% increase in diastolic blood pressure for Nordic Spirit 11.2 mg ONP 30 min post-exposure.
“3.9% increase in DBP for Nordic Spirit 11.2 mg ONP 30 min post-exposure”
From Comparison of the Health Effects Associated with the Use of Snus and Tobacco-Free Oral Nicotine Pouches: A Systematic Review (2026) · cites this paper as Renard et al. 2025
3% increase in systolic blood pressure for Nordic Spirit 9 mg ONP 30 min post-exposure.
“3% increase in SBP for Nordic Spirit 9 mg ONP 30 min post-exposure”
From Comparison of the Health Effects Associated with the Use of Snus and Tobacco-Free Oral Nicotine Pouches: A Systematic Review (2026) · cites this paper as Renard et al. 2025
7.4% increase in diastolic blood pressure for Nordic Spirit 9 mg ONP 30 min post-exposure.
“7.4% increase in DBP for Nordic Spirit 9 mg ONP 30 min post-exposure”
From Comparison of the Health Effects Associated with the Use of Snus and Tobacco-Free Oral Nicotine Pouches: A Systematic Review (2026) · cites this paper as Renard et al. 2025
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Lunell, E., Fagerström, K., Hughes, J., & Pendrill, R. (2020) · Nicotine & Tobacco Research · doi:10.1093/ntr/ntaa068 · Cited by 121 · see citing works
McEwan, M., Azzopardi, D., Gale, N., Camacho, O. M., Hardie, G., Fearon, I. M., & Murphy, J. (2022) · European Journal of Drug Metabolism and Pharmacokinetics · doi:10.1007/s13318-021-00742-9 · Cited by 70 · see citing works
Liu, J., Rensch, J., Wang, J., Jin, X., Vansickel, A., Edmiston, J., & Sarkar, M. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06172-y · Cited by 37 · see citing works
Flagged first, then by citations
Research works printed but not linked: 19
- Aldeek F, Mccutcheon N, Smith C, et al (2021) Dissolution Testing of Nicotine Release from OTDN Pouches: Product Characterization and Product-to-Product Comparison. 10.3390/separations80 · DOI
- Azzopardi D, Ebajemito J, McEwan M, et al (2022a) A randomised study to assess the nicotine pharmacokinetics of an oral nicotine pouch and two nicotine replacement therapy products. Sci Rep 12. 10.1038/s41598-022-10544-x PMC9050656 35484309 · DOI
- Azzopardi D, Haswell LE, Frosina J et al (2023) Assessment of biomarkers of exposure and potential harm, and physiological and subjective health measures in exclusive users of nicotine pouches and current, former and never smokers. Biomarkers 28:118–129. 10.1080/1354750X.2022.2148747 36484137 · DOI
- Azzopardi D, Liu C, Murphy J (2022b) Chemical characterization of tobacco-free “modern” oral nicotine pouches and their position on the toxicant and risk continuums. Drug Chem Toxicol 45:2246–2254. 10.1080/01480545.2021.1925691 34034614 · DOI · Paper page
- Back S, Masser AE, Rutqvist LE, Lindholm J (2023) Harmful and potentially harmful constituents (HPHCs) in two novel nicotine pouch products in comparison with regular smokeless tobacco products and pharmaceutical nicotine replacement therapy products (NRTs). BMC Chem 17. 10.1186/s13065-023-00918-1 PMC9985244 36869349 · DOI
- Cappelleri JC, Bushmakin AG, Baker CL et al (2007) Multivariate framework of the Brief Questionnaire of Smoking Urges. Drug Alcohol Depend 90:234–242. 10.1016/j.drugalcdep.2007.04.002 17482773 · DOI
- Chapman F, McDermott S, Rudd K et al (2022) A randomised, open-label, cross-over clinical study to evaluate the pharmacokinetic, pharmacodynamic and safety and tolerability profiles of tobacco-free oral nicotine pouches relative to cigarettes. Psychopharmacology 239:2931–2943. 10.1007/s00213-022-06178-6 35732751 PMC9217727 · DOI
- Dai X, Gil GF, Reitsma MB et al (2022) Health effects associated with smoking: a Burden of Proof study. Nat Med 28:2045–2055. 10.1038/s41591-022-01978-x 36216941 PMC9556318 · DOI
- Gottlieb S, Zeller M (2017) A Nicotine-Focused Framework for Public Health. N Engl J Med 377:1111–1114. 10.1056/NEJMp1707409 28813211 · DOI
- Hatsukami DK, Zhang Y, O’Connor RJ, Severson HH (2013) Subjective responses to oral tobacco products: Scale validation. Nicotine Tob Res 15:1259–1264. 10.1093/ntr/nts265 23239843 PMC3682844 · DOI
- Institute of Medicine (2001) Clearing the smoke: assessing the science base for tobacco harm reduction. National Academy Press, Washington, D.C. 25057541
- Lunell E, Curvall M (2011) Nicotine delivery and subjective effects of Swedish portion snus compared with 4 mg nicotine polacrilex chewing gum. Nicotine Tob Res 13:573–578. 10.1093/ntr/ntr044 21454913 · DOI · Paper page
- Miller-Holt J, Baskerville-Abraham I, Sakimura M et al (2022) In vitro evaluation of mutagenic, cytotoxic, genotoxic and oral irritation potential of nicotine pouch products. Toxicol Rep 9:1316–1324. 10.1016/j.toxrep.2022.06.008 36518473 PMC9742906 · DOI
- Pickworth WB, Rosenberry ZR, Gold W, Koszowski B (2014) Nicotine Absorption from Smokeless Tobacco Modified to Adjust pH. J Addict Res Ther 5:1000184. 10.4172/2155-6105.1000184 25530912 PMC4271311 · DOI
- Price LR, Martinez J (2019) Biological effects of nicotine exposure: A narrative review of the scientific literature. F1000Res 8:1586. 10.12688/f1000research.20062.1 PMC7308884 32595938 · DOI
- Rensch J, Edmiston J, Wang J et al (2023) A Randomized, Controlled Study to Assess Changes in Biomarkers of Exposures Among Adults Who Smoke That Switch to Oral Nicotine Pouch Products Relative to Continuing Smoking or Stopping All Tobacco Use. J Clin Pharmacol 63:1108–1118. 10.1002/jcph.2293 37322571 · DOI
- Rensch J, Liu J, Wang J et al (2021) Nicotine pharmacokinetics and subjective response among adult smokers using different flavors of on!® nicotine pouches compared to combustible cigarettes. Psychopharmacology 238:3325–3334. 10.1007/s00213-021-05948-y 34432106 · DOI · Paper page
- Stanfill S, Tran H, Tyx R et al (2021) Characterization of Total and Unprotonated (Free) Nicotine Content of Nicotine Pouch Products. Nicotine Tob Res 23:1590–1596. 10.1093/ntr/ntab030 34233354 · DOI
- Yu F, Rudd K, Pour SJ et al (2022) Preclinical Assessment of Tobacco-Free Nicotine Pouches Demonstrates Reduced in Vitro Toxicity Compared with Tobacco Snus and Combustible Cigarette Smoke. Appl in Vitro Toxicol 8:24–35. 10.1089/aivt.2021.0020 · DOI
Cited by
Sorted by citations
Kopa-Stojak, P. N., & Pawliczak, R. (2026) · Exposure and Health · doi:10.1007/s12403-026-00812-w
- Authors
- Renard, K., Nishihara, D., Nilsson, J., Larroque, S., Martinez, J., & Giles, L.
- Venue
- Psychopharmacology
- Published
- 2024-11-23
- Volume
- 242
- Issue
- 4
- Pages
- 855-865
- ISSN
- 0033-3158
- 1432-2072
- PMC
- PMC11890228
- Cited by
- 8
- References
- 3
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
